SCHEMBL3395751

SCHEMBL3395751

CC(=O)OCCCOc1c(C)[c]ncc1C

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.37
PDE3B Q13370 2/20 0.35
PDE3A Q14432 2/20 0.35
P2RY12 Q9H244 2/20 0.35
HTT P42858 1/20 0.34
KDM4E B2RXH2 2/20 0.34
APOBEC3A P31941 1/20 0.34
APOBEC3G Q9HC16 1/20 0.34
RAD52 P43351 1/20 0.33
MEN1 O00255 2/20 0.31
CYP1A2 P05177 2/20 0.31
KMT2A Q03164 2/20 0.31
TNKS2 Q9H2K2 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP3A4 P08684 1/20 0.30
CA2 P00918 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3393895 0.93 HTT (0.41) ALDH1A1PDE3BPDE3AP2RY12HTT
SCHEMBL3391484 0.72 KDM4E (0.31) ALDH1A1KDM4E
SCHEMBL315271 0.66 ALDH1A1 (0.74) ALDH1A1APOBEC3AAPOBEC3GTNKS2CA2
SCHEMBL10030195 0.64 L3MBTL1 (0.59) ALDH1A1PDE3BPDE3AP2RY12HTT
SCHEMBL3394614 0.64
Ammonia Solution, Strong SCHEMBL9807764 0.64 ALDH1A1 (0.70) ALDH1A1APOBEC3AAPOBEC3GTNKS2CA2
SCHEMBL313556 0.63
SCHEMBL14571065 0.63 L3MBTL1 (0.58) ALDH1A1PDE3BPDE3AP2RY12HTT
SCHEMBL11326783 0.63 MAPT (0.52) ALDH1A1KDM4ERAD52MEN1KMT2A
Acetic Acid SCHEMBL27535337 0.62 ALDH1A1 (0.67) ALDH1A1APOBEC3AAPOBEC3GTNKS2CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2145888-A1 Deazapurine derivatives as HSP90-Inhibitors Conforma Therapeutics Corporation (US) 2010-01-20 EP disclosed
US-20070185064-A1 2-Aminopurine Analogs Having HSP90-Inhibiting Activity CONFORMA THERAPEUTICS CORPORATION (US) 2007-08-09 US disclosed
US-7138401-B2 2-aminopurine analogs having HSP90-inhibiting activity CONFORMA THERAPEUTICS CORPORATION (US) 2006-11-21 US disclosed
US-20050113340-A1 2-Aminopurine analogs having HSP90-inhibiting activity CONFORMA THERAPEUTICS CORPORATION 2005-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113340-A1 2-Aminopurine analogs having HSP90-inhibiting activity HSP90AB2P, HSP90AB1, HSP90AA1 ALDH1A1 827/4885PDE3B 3393/4885PDE3A 2896/4885
US-20070185064-A1 2-Aminopurine Analogs Having HSP90-Inhibiting Activity HSP90AB2P, HSP90AB1, HSP90AA1 ALDH1A1 827/4885PDE3B 3393/4885PDE3A 2896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.